tirzepatide clinicaltrials gov Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial Tirzepatide vs. Retatrutide: Key Differences

Another 2024 clinical analysis reported that once GLP-1 receptor agonist treatment was discontinued, participants regained roughly half of the weight they had lost within 26 weeks

The potential buffering effect of food is far outweighed by the increased enzymatic activity and delayed gastric transit it causes

Inflammation is a problem in many different health conditions, so reducing it could be very helpful

The GLP1 Success Program is designed for people who are already taking GLP1 medications (such as Wegovy or Zepbound) through another provider and want expert nutritional and lifestyle support tailored to their needs